Investigation of the conformational dynamics of the apo A2A adenosine receptor

被引:10
作者
Caliman, Alisha D. [1 ]
Swift, Sara E. [1 ]
Wang, Yi [2 ]
Miao, Yinglong [2 ]
McCammon, J. Andrew [1 ,2 ,3 ]
机构
[1] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
关键词
GPCR; adenosine A(2A); activation; molecular dynamics; NPxxY; CENTRAL-NERVOUS-SYSTEM; CRYSTAL-STRUCTURE; MOLECULAR-DYNAMICS; ALLOSTERIC MODULATION; ACTIVATION; LYMPHOCYTES; SIMULATIONS; ALGORITHM; BINDING; FAMILY;
D O I
10.1002/pro.2681
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The activation/deactivation processes for G-protein coupled receptors (GPCRs) have been computationally studied for several different classes, including rhodopsin, the 2 adrenergic receptor, and the M2 muscarinic receptor. Despite determined cocrystal structures of the adenosine A(2A) receptor (A(2A)AR) in complex with antagonists, agonists and an antibody, the deactivation process of this GPCR is not completely understood. In this study, we investigate the convergence of two apo simulations, one starting with an agonist-bound conformation (PDB: 3QAK)(14) and the other starting with an antagonist-bound conformation (PDB: 3EML)(11). Despite the two simulations not completely converging, we were able to identify distinct intermediate steps of the deactivation process characterized by the movement of Y288(7.53) in the NPxxY motif. We find that Y288(7.53) contributes to the process by forming hydrogen bonds to residues in transmembrane helices 2 and 7 and losing these interactions upon full deactivation. Y197(5.58) also plays a role in the process by forming a hydrogen bond only once the side chain moves from the lipid interface to the middle of the helical bundle.
引用
收藏
页码:1004 / 1012
页数:9
相关论文
共 48 条
[2]  
Ballesteros J. A., 1995, METH NEUROSCI, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]
[3]   Adenosine receptors as drug targets - what are the challenges? [J].
Chen, Jiang-Fan ;
Eltzschig, Holger K. ;
Fredholm, Bertil B. .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) :265-286
[4]  
Chen Jiang-Fan, 2011, Handb Exp Pharmacol, P267, DOI 10.1007/978-3-642-13443-2_10
[5]   High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor [J].
Cherezov, Vadim ;
Rosenbaum, Daniel M. ;
Hanson, Michael A. ;
Rasmussen, Soren G. F. ;
Thian, Foon Sun ;
Kobilka, Tong Sun ;
Choi, Hee-Jung ;
Kuhn, Peter ;
Weis, William I. ;
Kobilka, Brian K. ;
Stevens, Raymond C. .
SCIENCE, 2007, 318 (5854) :1258-1265
[6]   Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design [J].
Congreve, Miles ;
Andrews, Stephen P. ;
Dore, Andrew S. ;
Hollenstein, Kaspar ;
Hurrell, Edward ;
Langmead, Christopher J. ;
Mason, Jonathan S. ;
Ng, Irene W. ;
Tehan, Benjamin ;
Zhukov, Andrei ;
Weir, Malcolm ;
Marshall, Fiona H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) :1898-1903
[7]   Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine [J].
Dore, Andrew S. ;
Robertson, Nathan ;
Errey, James C. ;
Ng, Irene ;
Hollenstein, Kaspar ;
Tehan, Ben ;
Hurrell, Edward ;
Bennett, Kirstie ;
Congreve, Miles ;
Magnani, Francesca ;
Tate, Christopher G. ;
Weir, Malcolm ;
Marshall, Fiona H. .
STRUCTURE, 2011, 19 (09) :1283-1293
[8]   Activation mechanism of the β2-adrenergic receptor [J].
Dror, Ron O. ;
Arlow, Daniel H. ;
Maragakis, Paul ;
Mildorf, Thomas J. ;
Pan, Albert C. ;
Xu, Huafeng ;
Borhani, David W. ;
Shaw, David E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (46) :18684-18689
[9]   A SMOOTH PARTICLE MESH EWALD METHOD [J].
ESSMANN, U ;
PERERA, L ;
BERKOWITZ, ML ;
DARDEN, T ;
LEE, H ;
PEDERSEN, LG .
JOURNAL OF CHEMICAL PHYSICS, 1995, 103 (19) :8577-8593
[10]   The G-protein Coupled Receptor Family: Actors with Many Faces [J].
George, Liapakis ;
Arnau, Cordomi ;
Leonardo, Pardo .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (02) :175-185